Acute coronary syndrome and myocardial infarction
93 results
1 - 93Acute coronary syndrome and myocardial infarction
Coronary heart disease
Diagnostic coronary angiography
For treatment of acute coronary syndrome, prasugrel is better than ticagrelor at preventing recurrent MIs at 1 year
Antithrombotic agents in primary health care
Bivalirudin = abciximab + heparin for non-STEMI
Drug‐eluting stents versus bare‐metal stents for acute coronary syndrome
Statins for acute coronary syndrome
Signs and symptoms not helpful in diagnosis of AMI/ACS
Early invasive therapy better for non-ST ACS
Dyspepsia
Intensive lipid lowering reduces mortality following ACS
Escitalopram reduces risk of adverse cardiac events in adults with depression and acute coronary syndrome
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
High-sensitivity troponin I of less than 5 ng/L has negative predictive value of 99.9% for cardiac death at 1 year
Two-hour protocol identifies patients at low risk of ACS
Early CT angiography for suspected acute coronary syndrome reduces further ischemic testing; no effect on long-term clinical outcomes
Accelerated protocol identifies chest pain patients at low risk for major cardiac events
Hyperbaric oxygen therapy for acute coronary syndrome
Clopidogrel monotherapy more effective than aspirin to prevent coronary events after PCI with drug-eluting stents (HOST-EXAM)
Pioglitazone does not increase cardiovascular events (PROactive)
Adding ezetimibe to moderate-dose statin reduces nonfatal MI only (NNT = 58 for 6 years)
Similar outcomes after PCI in hospitals with or without on-site cardiac surgery (CPORT-E)
Statins for acute coronary syndrome
Additional testing of limited benefit in patients with new-onset chest pain
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes: Cochrane systematic review
Clopidogrel plus aspirin vs aspirin alone for preventing cardiovascular events
High-sensitivity troponin safely reduces admissions and duration of stay in the emergency department
Intensive versus moderate statin therapy
Ticagrelor (Brilinta) is no better than aspirin—and may be worse—for adults after CABG
B vitamins, fish oil do not prevent CV events
Overuse alert: treat-to-target LDL strategy of statin dosing is noninferior to high-intensity dosing
Mortality rate in patients with recent ACS and endoscopy is similar to that in patients with ACS and no endoscopy
Acute abdomen in the adult
Flu vaccine reduces risk of adverse CV events in high-risk patients
Intensive BP control modestly decreased the likelihood of a broad composite of CV events, but with methodologic limitations
Exercise stress test
Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes: Cochrane systematic review
Adding CCTA to chest pain assessment reduces likelihood of nonfatal MI (SCOT-HEART)
6-month clopidogrel better than 24 after stent placement (PRODIGY)
Warfarin therapy
Lipid lowering is beneficial for secondary prevention but not primary prevention in patients 75 years and older
Dyspnoea
Drug treatment for hypertension
In patients with vascular disease, treating sleep apnea does not reduce the risk of cardiovascular events
Acute heart failure and pulmonary oedema
Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
Similar number of cardiovascular events and reduced bleeding with abbreviated dual antiplatelet therapy after PCI
Increased readmissions and adverse events with intensification of antihypertensive regimen on hospital discharge
Interpretation of adult ECG
Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
Chronic heart failure
SBP of 120 instead of 140 in adults 75 years or older = significant benefits and some harms (SPRINT)
Little if any benefit to early invasive strategy for stable angina and at least moderate reversible ischemia (ISCHEMIA trial)
SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
Treatment of dyslipidaemias
Final report from SPRINT: lowering SBP below 120 mm Hg decreases major adverse cardiac events and all-cause mortality
Transfusion thresholds for guiding red blood cell transfusion
Syncope: causes and investigations
Management of acute atrial fibrillation
Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
Overview of new ACC/AHA lipid guidelines: here we go again
Prehospital emergency care
For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
** Update Information **
COVID-19 and other coronavirus infections